Literature DB >> 15247367

Bone lesions in molecular subtypes of multiple myeloma.

Davide F Robbiani, Marta Chesi, P Leif Bergsagel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15247367     DOI： 10.1056/NEJM200407083510223

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 2.  Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.

Authors:  Fuling Zhou; Shan Meng; Huanjin Song; François X Claret
Journal:  Blood Rev       Date:  2013-09-02       Impact factor: 8.250

3.  A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.

Authors:  Ping Wu; Brian A Walker; Daniel Brewer; Walter M Gregory; John Ashcroft; Fiona M Ross; Graham H Jackson; Anthony J Child; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

Review 4.  Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma.

Authors:  Alessandro Allegra; Marco Casciaro; Paola Barone; Caterina Musolino; Sebastiano Gangemi
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

5.  Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Authors:  B Dalla Palma; D Guasco; M Pedrazzoni; M Bolzoni; F Accardi; F Costa; G Sammarelli; L Craviotto; M De Filippo; L Ruffini; P Omedè; R Ria; F Aversa; N Giuliani
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

6.  Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.

Authors:  Meera Mohan; Manoj Kumar; Rohan Samant; Rudy Van Hemert; Erming Tian; Shivang Desai; Frits van Rhee; Sharmilan Thanendrarajan; Carolina Schinke; Larry J Suva; Shobhit Sharma; Mohamed Milad; Samantha Kendrick; Maurizio Zangari
Journal:  Bone       Date:  2021-02-06       Impact factor: 4.398

7.  Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis.

Authors:  Jinxiang Fu; Panjun Wang; Xiaohui Zhang; Suguang Ju; Jie Li; Binzhou Li; Sun Yu; Jianhua Zhang; Xueguang Zhang
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

8.  Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

Authors:  Arnold Bolomsky; Dirk Hose; Martin Schreder; Anja Seckinger; Susanne Lipp; Bernard Klein; Daniel Heintel; Heinz Ludwig; Niklas Zojer
Journal:  J Hematol Oncol       Date:  2015-02-08       Impact factor: 17.388

Review 9.  The genetic architecture of multiple myeloma.

Authors:  Steven M Prideaux; Emma Conway O'Brien; Timothy J Chevassut
Journal:  Adv Hematol       Date:  2014-04-03

Review 10.  Glucocorticoids Influencing Wnt/β-Catenin Pathway; Multiple Sites, Heterogeneous Effects.

Authors:  Katalin Meszaros; Attila Patocs
Journal:  Molecules       Date:  2020-03-25       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.